The Danish endoscopy specialist has announced that if has received a 510(k) FDA clearance and CE mark for using its aScope 5 Broncho portfolio in pediatric airway procedures.
Thereby the single-use bronchoscopy portfolio will be available for patients from six months and up.
“This is in an important step in extending the reach and value of our leading single-use respiratory offering. With the pediatric indication, we can support clinicians across more procedures, patient groups and care settings while reinforcing the value single-use solutions bring through improved availability, workflow efficiency, and patient care,” Ambu CEO Britt Meelby Jensen said in a press release.
BREAKING